1. Introduction {#sec1-ijerph-16-01263}
===============

Electronic nicotine product use is increasing in the United States \[[@B1-ijerph-16-01263],[@B2-ijerph-16-01263]\] but few studies have addressed their toxicological effects on oral health \[[@B3-ijerph-16-01263]\]. Electronic nicotine products, commonly known as e-cigarettes, include a diverse group of battery-powered devices that allow users to vaporize and inhale an aerosol, which usually contains nicotine, flavorings, and other additives. These products vary in design and appearance, can sometimes be called other names such as e-cigars, e-pipes, e-hookahs, personal vaporizers, vape pens and hookah pens, but they generally contain similar components and operate in a similar manner \[[@B2-ijerph-16-01263]\].

Periodontal (or gum) disease is an infectious disease resulting in inflammation within the supporting tissues of the teeth, and progressive diminished tooth attachment and bone loss. It is characterized by pocket formation and/or gingival recession. Periodontal disease is a significant cause of tooth loss in the United States \[[@B4-ijerph-16-01263]\]. It also ranks among the top 100 causes of disability-adjusted life years globally \[[@B5-ijerph-16-01263]\]. Smoking is a major risk factor for periodontal disease \[[@B6-ijerph-16-01263]\] and may be responsible for more than half of periodontal disease cases among adults in the United States \[[@B7-ijerph-16-01263]\]. In vitro studies have shown that e-cigarette vapor can lead to inflammation of gingival epithelial cells similar to that observed in cells exposed to conventional cigarette smoke \[[@B8-ijerph-16-01263]\].

There have been numerous studies showing the deleterious effects of periodontal disease on overall health. Periodontal disease is associated with an increase in cardiac disease among individuals \>65 years of age \[[@B9-ijerph-16-01263]\], exacerbation of insulin resistance \[[@B10-ijerph-16-01263],[@B11-ijerph-16-01263]\] and increase in the risk of cardiorenal mortality for those with type 2 diabetes \[[@B12-ijerph-16-01263]\]. Adults with periodontal disease were more likely to have chronic kidney disease \[[@B13-ijerph-16-01263]\] and also a greater risk of mortality \[[@B14-ijerph-16-01263],[@B15-ijerph-16-01263]\]. Periodontal disease has also been shown to lead to a significant increase in the risk of oral cancer \[[@B16-ijerph-16-01263]\], a decrease in the cognitive function for the elderly \[[@B17-ijerph-16-01263],[@B18-ijerph-16-01263]\] and an accumulation of amyloid β plaques which is a central feature of Alzheimer's disease \[[@B19-ijerph-16-01263]\].

Very few studies have investigated the effects of e-cigarette use on oral health, and most of these studies have been limited by few participants. One recent study suggested that e-cigarette use may not be as hazardous to periodontal health as cigarette smoking, and e-cigarette users may have periodontal status comparable to non-smokers \[[@B20-ijerph-16-01263]\]. Another study showed a progressive improvement in the periodontal indexes for cigarette smokers who switched to e-cigarettes for approximately 4 months before the study \[[@B21-ijerph-16-01263]\]. However, another study showed a statistically significant increase in gingival inflammation in tobacco smokers who switched from smoking to vaping for two weeks \[[@B22-ijerph-16-01263]\]. A larger cross-sectional analysis using the 2016 Behavioral Risk Factor Surveillance System survey data showed an increased odds of teeth loss due to decay or gum disease with the use of e-cigarettes \[[@B23-ijerph-16-01263]\].

The aim of this study was to examine the association between electronic nicotine product use and new cases of gum disease in a large, nationally representative sample, using data from the Population Assessment of Tobacco and Health (PATH) study. The hypothesis was that the use of electronic nicotine products would be associated with increased odds of gum disease and bone loss around teeth, even after controlling for use of conventional cigarettes and other known risk factors. Sub-group analysis was also performed to examine this association in participants who had a history of marijuana use and a history of illicit or non-prescribed drug use.

2. Material and Methods {#sec2-ijerph-16-01263}
=======================

Public use PATH survey data from 12 September 2013 to 14 December 2014 (wave 1), 23 October 2014 to 30 October 2015 (wave 2), and 19 October 2015 to 23 October 2016 (wave 3) was used for the analysis \[[@B24-ijerph-16-01263]\]. The PATH survey is a nationally representative, longitudinal cohort study of tobacco-use patterns and the health of non-institutionalized adults (≥18 years) and youths (12--17 years) in the United States. The PATH survey collects interview data through in-person computer-assisted personal interviewing and audio computer-assisted self-interviewing methods. All wave 1 respondents were eligible for the wave 2 and 3 interview as long as they continued to live in the United States and were not incarcerated. There were 32,320 adults in wave 1, 28,362 adults in wave 2, and 28,148 adults in wave 3. The 23,670 adults that completed waves 1, 2 and 3 interviews were used for the study. Weights were used to compensate for differential nonresponse rates, variable probabilities of selection and possible deficiencies in sampling. More details about the PATH study design and methods are published elsewhere \[[@B25-ijerph-16-01263]\].

2.1. Inclusion Criteria {#sec2dot1-ijerph-16-01263}
-----------------------

We included the following participants in our analysis:(1)Adults who completed Waves 1, 2 and 3 of the PATH survey.(2)Participants who reported ever having had their teeth cleaned by a dentist, hygienist, or other health professionals by wave 3.(3)Participants who reported no history of "gum disease" at baseline (wave 1).

2.2. Data and Definitions {#sec2dot2-ijerph-16-01263}
-------------------------

Data was collected on the age, sex, race, highest grade completed, income level, current tobacco use, current second-hand exposure to tobacco smoke (cigarettes, cigars, filtered cigars or cigarillos), use of nicotine replacement therapy products, marijuana use, alcohol use, illicit and non-prescribed drug use, visits to the dentist and medical history as of wave 1.

Participants with a history of marijuana use in wave 1 reported "ever smoking part or all of a cigar, cigarillo or filtered cigar with marijuana in it" or "having ever used marijuana, hash, THC or grass". Participants with a history of illicit drug use in wave 1 reported ever having used any of the following substances: cocaine or crack, stimulants like methamphetamine or speed or drugs like heroin, inhalants, solvents, or hallucinogens. Participants with a history of non-prescribed drug use in wave 1 reported ever having used painkillers, sedatives, tranquilizers, Ritalin or Adderall not prescribed to them or using the drugs "for the experience or feeling they caused".

2.3. Longitudinal Product Use {#sec2dot3-ijerph-16-01263}
-----------------------------

Regular electronic nicotine product users were participants who said yes to using "electronic nicotine products (such as e-cigarettes, vape pens, personal vaporizers and mods, e-cigars, e-pipes, e-hookahs and hookah pens) fairly regularly every day or some days. Longitudinal electronic nicotine product users were participants who were regular electronic nicotine product users in all the three waves of the PATH survey. Longitudinal conventional cigarette users were participants who have smoked more than 100 cigarettes in their lifetime and smoked every day or someday in all the three waves of the PATH survey.

2.4. Outcomes {#sec2dot4-ijerph-16-01263}
-------------

Participants with new cases of gum disease reported having been told by a dentist, hygienist, or other health professionals in the past 12 months that they had "gum disease" in wave 2 or 3 while also reporting no history of "gum disease" in wave 1. Participants with bone loss around teeth reported having ever been told by a dentist, hygienist, or other health professionals that they lost bone around their teeth in wave 3 (this question was first added to the survey in wave 3). Participants with any periodontal disease reported bone loss around teeth or new cases of gum disease in wave 2 or 3.

2.5. Statistical Analyses {#sec2dot5-ijerph-16-01263}
-------------------------

Descriptive statistics of never electronic nicotine product, longitudinal electronic nicotine product and non-longitudinal electronic nicotine product users' demographics, tobacco use and medical history were calculated. Non-longitudinal electronic nicotine product users comprise of ever electronic nicotine product users that did not use electronic nicotine product regularly every day or somedays in waves 1, 2 and 3. Continuous variables were analyzed using Student's t-test and categorical variables were analyzed using chi-square test ([Table 1](#ijerph-16-01263-t001){ref-type="table"}).

Multivariable logistic regression was used to examine the association between longitudinal electronic nicotine product use and new cases of gum disease, bone loss around teeth and any periodontal disease after controlling for the confounding factors listed in [Table 1](#ijerph-16-01263-t001){ref-type="table"}. All the covariates in [Table 1](#ijerph-16-01263-t001){ref-type="table"} were included in the multivariable regression models.

For the secondary analysis, multivariable logistic regression was also used to examine the association between longitudinal electronic nicotine product use and new cases of gum disease, bone loss around teeth and any periodontal disease in two subgroups. The subgroups were participants that had a history of marijuana use and a history of illicit or non-prescribed drug use. Confounding factors listed in [Table 1](#ijerph-16-01263-t001){ref-type="table"} were also controlled for in the analysis.

Replicate weights and balanced repeated replication methods were used for the analysis in order to account for the PATH study design. Participants with missing values were removed from the analysis. All analyses were conducted using R version 3.4.2 (R Core Team, Vienna, Austria). Statistical significance was defined as a two-tailed *p*-value of \< 0.05.

3. Results {#sec3-ijerph-16-01263}
==========

A total of 18,289 participants who met the inclusion criteria were included in the analysis. [Figure 1](#ijerph-16-01263-f001){ref-type="fig"} shows the selection process for the participants. There were 329 participants who reported longitudinal electronic nicotine product use, 8298 participants who reported non-longitudinal electronic nicotine product use and 9632 participants who reported never electronic nicotine product use. [Table 1](#ijerph-16-01263-t001){ref-type="table"} shows the descriptive statistics for the baseline characteristics and outcomes for participants used in the analysis.

Among the participants with no gum disease at baseline, 46.3% (95% CI 45.8 -- 46.9) were men, 0.9% (95% CI 0.8--1.0) were longitudinal electronic nicotine product users, 23.6% (95% CI 22.9--24.4) were non-longitudinal electronic nicotine product users, 75.5% (95% CI 74.7--76.2) were never electronic nicotine product user and 13.0% (95% CI 12.5--13.5) were longitudinal conventional cigarette users. Among participants with no gum disease at baseline, 5.4% (95% CI 5.0--5.8) reported new cases of gum disease at waves 2 and 3, 8.2% (95% CI 7.6--8.9) reported ever having bone loss around teeth at wave 3 and 11.3% (95% CI 10.9--12.4) reported any periodontal disease at waves 2 or 3.

Longitudinal electronic nicotine product users had increased odds of being diagnosed with gum disease (OR 1.76, 95% CI 1.12--2.76), bone loss around the teeth (OR 1.67, 95% CI 1.06--2.63) and any periodontal disease (OR 1.58, 95% CI 1.06--2.34) compared to never-electronic nicotine product users after adjusting for longitudinal cigarette use and other confounding factors. The odds of being diagnosed with gum disease and bone loss were slightly higher for participants that had a history of marijuana use and a history of illicit or non-prescribed drug use ([Table 2](#ijerph-16-01263-t002){ref-type="table"}).

4. Discussion {#sec4-ijerph-16-01263}
=============

We showed that participants with no history of gum disease who used electronic nicotine products regularly every day or somedays for a year or more had increased odds of being diagnosed with gum disease, even after controlling for conventional cigarette smoking and other known risk factors. The participants who used electronic nicotine products also had an increased odds of reporting bone loss around teeth which is indicative of advanced periodontal disease. The odds were higher for participants who had a history of marijuana use or any illicit and non-prescribed drug use. This study helps to fill a gap identified in the literature about the effect of electronic nicotine products use on oral health \[[@B26-ijerph-16-01263]\].

Marijuana use \[[@B27-ijerph-16-01263]\] and illicit drug use \[[@B28-ijerph-16-01263]\] have been implicated as risk factors for periodontal disease. Therefore, it is reasonable for our findings to show that these groups have higher odds of having periodontal disease with the use of electronic nicotine products. Our study shows that the co-use of electronic nicotine products with marijuana or illicit or non-prescribed drugs may amplify the risk of periodontal disease.

In vitro studies support the association that we found between electronic nicotine product use and periodontal disease. E-cigarette vapor has been shown to promote cell apoptosis, necrosis \[[@B8-ijerph-16-01263]\] and persistent DNA damage in gingival epithelium \[[@B29-ijerph-16-01263]\]. Menthol flavoring in e-cigarette liquid has also been shown to reduce the proliferation rate of human periodontal ligament fibroblasts \[[@B30-ijerph-16-01263]\]. Nicotine found in many e-cigarette aerosols \[[@B31-ijerph-16-01263]\] has been shown to inhibit the growth of gingival fibroblasts \[[@B32-ijerph-16-01263]\], human periodontal ligament cells \[[@B33-ijerph-16-01263]\] and alter the function of oral or peripheral neutrophils \[[@B34-ijerph-16-01263]\].

E-cigarettes have been perceived as less harmful than conventional cigarette smoking \[[@B35-ijerph-16-01263]\], and reported by some as a safer alternative to cigarette smoking \[[@B36-ijerph-16-01263]\] but e-cigarettes and other electronic nicotine products may still be deleterious to human health. Harmful or potentially harmful compounds such tobacco-specific nitrosamines, polycyclic aromatic hydrocarbons, metals and volatile organic compounds have been documented in some electronic nicotine product aerosols and the urine of e-cigarette users \[[@B1-ijerph-16-01263],[@B37-ijerph-16-01263]\].

One strength of the study was the large number of participants available for the analysis, who were nationally representative of the United States, non-institutionalized adult population. Also the data was longitudinal, which allowed us to investigate the association between the use of electronic nicotine products and a diagnosis of gum disease and bone loss around the teeth for participants who had no reported history of gum disease. Some of the limitations of our study were the fact that the survey results could be affected by recall bias by the participants. There could also be diagnosis misclassification bias by the participants. "Regular use of electronic nicotine product" may be interpreted different by the participants. Ideally, quantifiable numbers such as electronic nicotine product use per week would have been interpreted better by the participants. Additionally, some of the participants may have had gum disease in wave 1 but were not aware of it. Also some participants with advanced periodontal disease such as bone loss around the teeth may have reported no gum disease in waves 2 or 3.

5. Conclusions {#sec5-ijerph-16-01263}
==============

Our study with a nationally representative population indicates that electronic nicotine product use is associated with increased risk of developing periodontal disease even after accounting for the use of other tobacco products and other confounders. More research is necessary to assess the long-term effects and the safety of electronic nicotine products on oral health. Medical professionals should consider impact on oral health when educating and advising their patients about electronic nicotine product use.
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###### 

Demographic characteristics and health history of adult electronic nicotine product users and controls at baseline (wave 1).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                            Never Electronic Nicotine Product User N = 9632\   Longitudinal Electronic Nicotine Product User N = 329\   Non Longitudinal Electronic Product User N = 8298\
                                                                            % (95% CI)                                         % (95% CI)                                               % (95% CI)
  ------------------------------------------------------------------------- -------------------------------------------------- -------------------------------------------------------- ----------------------------------------------------
  **Age group**                                                                                                                                                                         

  18 to 24 years old                                                        9.6 (9.2--10)                                      23.8 (19.5--28.2)                                        30.8 (29.8--31.8)

  25 to 34 years old                                                        15.7 (14.8--16.6)                                  30.8 (24.4--37.1)                                        29 (27.8--30.3)

  35 to 44 years old                                                        17.4 (16.5--18.3)                                  15.9 (10.5--21.3)                                        16.6 (15.6--17.6)

  45 to 54 years old                                                        19.3 (18.5--20.1)                                  14.4 (9.5--19.3)                                         12.4 (11.6--13.3)

  55 years old or older                                                     38 (37--39)                                        15.1 (11.6--18.5)                                        11.1 (10.2--12)

  **Gender**                                                                                                                                                                            

  Female                                                                    55.6 (54.9--56.3)                                  46.8 (40.3--53.3)                                        47.7 (46.6--48.8)

  Male                                                                      44.4 (43.7--45.1)                                  53.2 (46.7--59.7)                                        52.3 (51.2--53.4)

  **Race**                                                                                                                                                                              

  White                                                                     79.9 (79.1--80.7)                                  86 (82--90)                                              76.7 (75.3--78.1)

  Black                                                                     11 (10.5--11.5)                                    5.3 (3--7.5)                                             13.3 (12.3--14.3)

  Other                                                                     9.1 (8.5--9.7)                                     8.8 (5.4--12.1)                                          10 (9.1--10.9)

  Hispanic                                                                  13.8 (13.2--14.3)                                  8.6 (5.6--11.6)                                          15.7 (14.7--16.7)

  **Highest Grade of Education**                                                                                                                                                        

  Less than High School                                                     9 (8.5--9.6)                                       5.4 (3.1--7.6)                                           9.9 (9.3--10.5)

  General Education Diploma (GED)                                           3.6 (3.1--4)                                       5.9 (3.2--8.6)                                           7.6 (6.8--8.3)

  High school graduate                                                      23.1 (22.4--23.9)                                  20.3 (15.7--24.9)                                        25 (23.8--26.3)

  Some college or associates degree                                         29.5 (28.8--30.1)                                  47.3 (40.8--53.8)                                        40.6 (39.3--41.9)

  Bachelor's degree or higher                                               34.8 (34.2--35.4)                                  21.1 (15.9--26.4)                                        16.9 (15.7--18)

  Body Mass Index (mean)                                                    28.0 (27.8--28.2)                                  27.8 (27.0--28.5)                                        27.5 (27.3--27.7)

  **Income**                                                                                                                                                                            

  Less than \$10,000                                                        9.8 (9--10.6)                                      13.5 (9.2--17.7)                                         18.8 (17.8--19.8)

  \$10,000 to \$24,999                                                      16.9 (15.8--18)                                    23 (18.1--28)                                            23.5 (22.2--24.7)

  \$25,000 to \$49,999                                                      22.2 (20.9--23.5)                                  26.9 (20.7--33.1)                                        24.1 (23--25.2)

  \$50,000 to \$99,999                                                      29.2 (27.7--30.7)                                  25.6 (20.1--31.1)                                        21.6 (20.4--22.9)

  \$100,000 or more                                                         21.9 (20.5--23.3)                                  11 (7.2--14.9)                                           12 (10.9--13.1)

  Baseline visit to the dentist ^1^                                         69.4 (68.2--70.6)                                  56.9 (51.3--62.4)                                        54.3 (52.8--55.8)

  Longitudinal visit to dentist ^2^                                         76.4 (75.2--77.6)                                  67.3 (61--73.6)                                          63.5 (62.1--64.8)

  History of prescription drug abuse                                        11.5 (10.7--12.3)                                  34.6 (28.4--40.7)                                        28.5 (27--29.9)

  History of stomach, duodenal or peptic ulcer                              7 (6.2--7.9)                                       9.4 (5.8--13)                                            6.7 (6.1--7.4)

  History of respiratory disease ^3^                                        13.6 (12.7--14.5)                                  20.1 (16--24.2)                                          16.9 (16.1--17.7)

  History of diabetes                                                       13.7 (12.6--14.7)                                  6.7 (3.9--9.4)                                           8.4 (7.6--9.2)

  History of high blood pressure                                            28.1 (27--29.2)                                    21.8 (17.2--26.4)                                        18.2 (17.1--19.3)

  History of high cholesterol                                               24.4 (23.3--25.5)                                  13.8 (10.1--17.5)                                        12.8 (11.8--13.9)

  Longitudinal conventional cigarette user                                  4.3 (4.0--4.6)                                     38.6 (32.1--45.1)                                        40.1 (38.7--41.4)

  Former conventional cigarette user ^4^                                    20.5 (19.2--21.9)                                  38.6 (32.5--44.7)                                        14.5 (13.5--15.5)

  History of marijuana use                                                  28.5 (27--29.9)                                    70.2 (64.3--76.1)                                        66.3 (64.8--67.8)

  History of alcohol use                                                    80 (77.9--82.1)                                    91.4 (87.8--95)                                          90.6 (89.9--91.4)

  History of other tobacco or tobacco product replacement therapy use ^5^   42.3 (40.7--43.8)                                  89.3 (85.3--93.3)                                        85.5 (84.3--86.7)

  History of illicit drug use                                               9.2 (8.3--10.1)                                    29.8 (24.3--35.2)                                        25.7 (24.4--27)

  History of current second hand exposure to tobacco smoke ^6^              14.8 (13.8--15.8)                                  39.3 (33--45.7)                                          41.4 (40--42.8)

  **Outcomes**                                                                                                                                                                          

  New cases of gum disease ^7^                                              5.1 (4.5--5.6)                                     9.8 (6.4--13.3)                                          6.2 (5.6--6.7)

  Bone loss around teeth ^8^                                                8.4 (7.6--9.2)                                     11.2 (7.6--14.8)                                         7.3 (6.6--8.1)

  Any periodontal disease ^9^                                               11.7 (10.8--12.6)                                  16.7 (12.2--21.2)                                        11.4 (10.6--12.2)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All the covariates in [Table 1](#ijerph-16-01263-t001){ref-type="table"} were included in the multivariable regression models. ^1^ Saw a dentist in the past 12 months in wave 1. ^2^ Saw a dentist in the past 12 months in either wave 2 or wave 3. ^3^ Reported being told by a doctor or health professional that they had any of the following: COPD, chronic bronchitis, emphysema or asthma in wave 1. ^4^ Smoked more than 100 cigarettes in lifetime, and now does not smoke at all in wave 1. ^5^ Reported ever using any of the following products: Traditional or filtered cigars, cigarillos, pipe, hookah, smokeless tobacco, snus, dissolvable tobacco and nicotine patch, gum, inhaler, nasal spray, lozenge or pill in wave 1. ^6^ Reported living with someone that smokes cigarettes, cigars, cigarillos or filtered cigars in wave 1. ^7^ Reported new cases gum disease in wave 2 or 3. ^8^ Reported bone loss in wave 3. ^9^ Reported bone loss around teeth in wave 3 or new cases of gum disease in wave 2 or 3.
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###### 

Results of the Multivariable Logistic Regression Models.

                                                                 Odds Ratio (95% Confidence Interval)                           
  -------------------------------------------------------------- -------------------------------------- ----------------------- -----------------------
  **Entire cohort (N = 18,259)**                                                                                                
  Never electronic nicotine product user                         Reference                              Reference               Reference
  Longitudinal electronic nicotine product user                  1.76 (1.12--2.76) ^2^                  1.67 (1.06--2.63) ^2^   1.58 (1.06--2.34) ^2^
  Non longitudinal electronic product user                       1.09 (0.87--1.35)                      1.10 (0.91--1.33)       1.09 (0.93--1.29)
  **History of marijuana use (N = 9325)**                                                                                       
  Never electronic nicotine product user                         Reference                              Reference               Reference
  Longitudinal electronic nicotine product user                  1.95 (1.14--3.34) ^2^                  1.91 (1.15--3.19) ^2^   1.91 (1.22--2.99) ^2^
  Non longitudinal electronic product user                       0.91 (0.69--1.21)                      1.16 (0.90--1.50)       1.06 (0.86--1.30)
  **History of illicit or non-prescribed drug use (N = 5410)**                                                                  
  Never electronic nicotine product user                         Reference                              Reference               Reference
  Longitudinal electronic nicotine product user                  2.38 (1.33--4.26) ^2^                  1.88 (1.01--3.48) ^2^   2.24 (1.40--3.60) ^2^
  Non longitudinal electronic product user                       1.00 (0.71--1.40)                      1.37 (0.99--1.89)       1.25 (0.96--1.62)

^1^ Bone loss around teeth in wave 3 or new cases of gum disease in wave 2 or 3. ^2^ Statistically significant results.
